Episode 37: Research Highlights from the American Academy of Dermatology Meeting 2024

Five GPER staff members attended the American Academy of Dermatology conference in February, the biggest gathering of dermatologists worldwide.  We bring you the newest treatments and latest research straight from the source.  Join our conversation with GPER staffers Korey Capozza, Kara Orevillo, Christine Cutaran and Michelle Tu about what stood out this year.  (And if you like our podcast, consider supporting it with a tax deductible donation). Read the transcript.

Literature mentioned in this episode:

A Phase 3 Trial of Nemolizumab

A Phase 3 Trial of Lebrikizumab

Tapinarof cream for moderate-to-severe atopic dermatitis

Previous
Previous

Episode 38: New Eczema Guidelines from the Allergy Societies: Takeaways and Surprises

Next
Next

Episode 36: Is the gut microbiome the key to allergic diseases?